Chen, Fangfang
Kolben, Thomas
Meister, Sarah
Czogalla, Bastian
Kolben, Theresa M.
Hester, Anna
Burges, Alexander
Trillsch, Fabian
Schmoeckel, Elisa
Mayr, Doris
Mayerhofer, Artur
Mahner, Sven
Jeschke, Udo
Beyer, Susanne http://orcid.org/0000-0001-8603-6714
Funding for this research was provided by:
german israeli foundation (GIF I-1417-201.2/2017, GIF I-1417-201.2/2017)
China Scholarship Council
Ludwig-Maximilians-Universität München
Article History
Received: 3 January 2021
Accepted: 15 September 2021
First Online: 6 December 2021
Declarations
:
: T. Kolben: holds stock of Roche, relative employed at Roche. T.M.Kolben: holds stock of Roche, employed at Roche. A. Burges: receives advisory board and honoraria from AstraZeneca, Roche and Tesaro. F. Trillsch: declares Research support, advisory board, honoraria and travel expenses from AstraZeneca, Clovis, Medac, PharmaMar, Roche, Tesaro. S.Mahner: receives Research support, advisory board, honoraria and travel expenses from AstraZeneca, Clovis, Eisai, GlaxoSmithKline, Medac, MSD, Novartis, Olympus, PharmaMar, Roche, Sensor Kinesis, Teva, Tesaro¸ All other authors declare that they have no conflict of interest.
: All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the Bioethics Committee of the Ludwig-Maximilians University of Munich (reference number 227–09 and 18–392).
: The study was approved by the ethics committee of the Ludwig-Maximilians University Munich (reference number: 048–08; 2008). Patient data were anonymized.
: Not applicable as all data are anonymized.
: Not applicable as all data are anonymized.